Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

690
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
690
Positron Emission Tomography01:29

Positron Emission Tomography

7.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Imaging and Radioligand Therapies in Pheochromocytomas and Paragangliomas.

Endocrine-related cancer·2026
Same author

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same author

Fully GMP-complient radiosynthesis of [<sup>161</sup>Tb]Tb-PSMA-1 using the miniAiO synthesizer for clinical translation.

EJNMMI radiopharmacy and chemistry·2026
Same author

Prospective study on the [<sup>18</sup>F]FDOPA PET/CT role in the management of medullary thyroid cancer patients with high residual calcitonin level after surgery.

European journal of nuclear medicine and molecular imaging·2026
Same author

A computational framework for optimizing radioiodine therapy protocols in metastatic thyroid cancer.

Scientific reports·2026
Same author

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

BMC cancer·2026

Related Experiment Video

Updated: Mar 10, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.1K

PET imaging for thyroid cancers: Current status and future directions.

Anne-Laure Giraudet1, David Taïeb2

  • 1Centre de médecine nucléaire LUMEN, centre Léon-Bérard, 15, rue Gabriel-Sarrazin, 69008 Lyon, France.

Annales D'Endocrinologie
|December 20, 2016
PubMed
Summary

Positron emission tomography-computed tomography (PET/CT) offers valuable insights into thyroid cancer progression. Different radiopharmaceuticals like 18F-FDG and 18F-FDOPA aid in staging, prognosis, and detecting persistent or recurrent disease.

Keywords:
Cancer thyroïdienFDG-PETFDOPAIode-124Iodine-124TEP-FDGThyroid carcinoma

More Related Videos

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
05:41

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

1.2K
High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model
03:41

High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model

Published on: October 11, 2022

2.4K

Related Experiment Videos

Last Updated: Mar 10, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.1K
Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
05:41

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

1.2K
High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model
03:41

High-Resolution Ultrasonography for the Analysis of Orthotopic ATC Tumors in a Genetically Engineered Mouse Model

Published on: October 11, 2022

2.4K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiology

Background:

  • Thyroid cancers require accurate staging and monitoring for effective treatment.
  • Positron emission tomography-computed tomography (PET/CT) integrates functional and anatomical imaging for in vivo molecular insights.
  • Various radiopharmaceuticals are being explored for their utility in thyroid cancer management.

Purpose of the Study:

  • To review the role of PET/CT in the evaluation of thyroid cancers.
  • To highlight the applications of specific radiopharmaceuticals in different types of thyroid carcinomas.
  • To discuss the diagnostic capabilities and limitations of PET/CT in thyroid cancer follow-up.

Main Methods:

  • Utilizing 18F-FDG PET/CT for staging, prognosis, and follow-up of poorly differentiated and metastatic thyroid carcinomas.
  • Employing 18F-FDG PET/CT for localization of persistent or recurrent disease, considering tumor burden and histology.
  • Investigating Iodine-124 (124I) for diagnostic purposes and pretherapeutic dosimetry.
  • Using 18F-FDOPA PET/CT for detecting persistent/recurrent medullary thyroid carcinoma (MTC), noting sensitivity dependence on calcitonin levels.
  • Applying 18F-FDG PET/CT in MTC cases with short calcitonin or CEA doubling times.

Main Results:

  • 18F-FDG PET/CT is recommended for staging, prognostic evaluation, and follow-up of metastatic/poorly differentiated thyroid cancers.
  • 18F-FDG PET/CT aids in localizing persistent/recurrent disease, though sensitivity varies with tumor characteristics.
  • 124I is under evaluation for diagnosis and dosimetry planning.
  • 18F-FDOPA PET/CT is highly sensitive for MTC recurrence, with sensitivity linked to calcitonin levels (>150pg/mL).
  • 18F-FDG PET/CT can be used in MTC with rapid calcitonin or CEA doubling times.

Conclusions:

  • PET/CT, utilizing various radiotracers, plays a crucial role in the comprehensive management of thyroid cancers.
  • The choice of radiopharmaceutical depends on the specific type of thyroid cancer and clinical scenario.
  • PET/CT provides essential molecular information for diagnosis, staging, and monitoring of thyroid malignancies.